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Objective: To assess the efficacy, tolerability and safety of cannabinoids (phyto- and syntheto-) 
in the management of rheumatic diseases. 
 
Methods: Multiple databases including Medline, EMBASE and CENTRAL were searched. 
Randomized controlled trials (RCTs) with outcomes of pain, sleep, quality of life, tolerability 
(drop outs due to adverse events) and safety (serious adverse events), with comparison of 
cannabinoids with any type of control were included. Study methodology quality was evaluated 
with the Cochrane risk of bias tool.  
 
Results: In four short term studies comprising 201 patients,  (58 RA, 71 FM, and 74 OA), 
cannabinoids had a statistically significant effect on pain in two, sleep in two and improved 
quality of life in one, with the study in OA prematurely terminated due to futility. The risk of 
bias was high for all three completed studies.  Dizziness, cognitive problems and drowsiness, as 
well as nauseawere reported for almost half of the patients. No serious adverse events were 
reported for cannabinoids during study duration. No studies of herbal cannabis were identified.  
 
Conclusion: Extremely small sample sizes, short study duration, heterogeneity of rheumatic 
conditions and products, and absence of study of herbal cannabis, allow for only limited 
conclusions for the effects of cannabinoids in rheumatic conditions. Pain relief and effect on 
sleep may have some potential therapeutic benefit, but with considerable mild to moderate 
adverse events. There is currently insufficient evidence to recommend cannabinoid treatments 
for management of rheumatic diseases pending further study.  
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SIGNIFICANCE AND INNOVATIONS 
 
• The human endocannabinoid system modulates the body towards homeostasis with 
effects on pain, inflammation and sleep. 
• There are limited studies of the effects of exogenous cannabinoids  in the management of 
symptoms of rheumatic diseases 
• The existing evidence for effects on pain and sleep is poor, although cannabinoids may 
hold potential pending further study. Neurocognitive and gastrointestinal adverse effects 
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Rheumatic diseases are an important cause of chronic pain, with imperfect response to current 
analgesic pharmacologic treatments. Recent study has identified an extensive endocannabinoid 
system in the animal kingdom, comprised of endogenous ligands and receptors throughout the 
organism, but with important localization to nervous tissue. The primary function of this system 
in the developed human being is to maintain homeostasis, which includes modulation of pain and 
inflammation [1]. Exogenous molecules with cannabinoid properties may therefore also function 
to engage this system, with particular interest in the effects on pain. Originally available as the 
herbal preparation derived from the hemp plant Cannabis sativa, cannabinoids have been used 
through the ages for alleged therapeutic effects. Currently, musculoskeletal pain is a common 
reason why persons use herbal cannabis for medicinal reasons [2-5]. With use of the herbal 
product as a means of self-medication by up to 10% of persons with chronic noncancer pain in 
Canada pain, pharmaceutical preparations have been developed and are now available for certain 
indications in some countries [6]. Therefore it is timely to examine the evidence for effect of the 
various cannabinoid molecules in persons with rheumatic diseases [7]. 
 
Cannabinoids exist as endocannabinoids which are natural regulatory molecules produced in our 
bodies, phytocannabinoids derived from the plant material or as synthesized pharmaceutical 
preparations, synthetocannabinoids [8]. The effects of herbal cannabis are mediated via plant 
alkaloids with two molecules, namely delta-9 tetrahydrocannabinol (∆
9
-THC) and cannabidiol 
(CBD), having particular interest for therapeutic effects [9-11]. Analogues of mostly THC have 
been synthesized, allowing for administration of defined amounts, compared to the variable 
composition of naturally occurring herbal products. Current preparations are available as four 
products; the herbal product administered by a weight measurement in grams, and three 
pharmacologic preparations; two synthetic oral agents, dronabinol, a stereoisomer of ∆
9
-THC, 
and nabilone, a synthetic analogue of ∆
9
-THC, and an oromucosal spray of cannabis extract, 
nabiximol, a combination of ∆
9
-THC and CBD, as well as trace amounts of minor 
phytocannabinoids [7]. Several drugs under development manipulate the endocannabinoid 
system by inhibiting enzymes that hydrolyze endocannabinoids and thereby boost the levels of 
the endogenous molecules. Blockade of the catabolic enzyme fatty acid amide hydrolase 
(FAAH) elevates anandamide levels and elicits antinociceptive effects, without the 
psychomimetic side effects associated with ∆
9
-THC [12].  
As this class of molecules may hold potential for symptom relief for pain related to rheumatic 
conditions, we have examined the literature for evidence of effects for cannabinoids as a therapy 
for patients with rheumatic diseases, which include inflammatory arthritis, peripheral 
osteoarthritis, soft tissue rheumatism and fibromyalgia. 
 
MATERIALS AND METHODS 
The Canadian Rheumatology Association (CRA), in response to the Government of Canada 
decision to revise its herbal cannabis for medicinal use policies, mandated this systematic review 
to better understand the use of cannabinoids pertaining to the management of persons with 
rheumatic diseases. Rheumatic diseases were defined as conditions affecting the musculoskeletal 
system, including systemic rheumatic diseases, osteoarthritis of peripheral and spinal regions, 
soft tissue rheumatism and fibromyalgia. As a preliminary step, the CRA convened a working 
group to conduct a needs assessment regarding rheumatologist confidence regarding cannabinoid 
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preparations in general and herbal cannabis in particular. Rheumatologists reported considerable 
lack of confidence in their knowledge of cannabinoids in general and in their ability to provide 
advice regarding use of cannabinoids for rheumatology patients in general [13]. Thereafter a 




Identification of studies 
A comprehensive literature search of the following databases was conducted in September 2013 
and further updated in January 2015 : MEDLINE (via OvidSP 1946 to 25/Sep/2013; via PubMed 
1946 to 26/Sep/2013) ; Embase Classic + Embase (via OvidSP 1947 to 24/Sep/2013); BIOSIS 
Previews (via OvidSP 1969 to 2013 Week 43); Web of Science (via ThomsonReuters 1996 to 
29/Sep/2013); Scopus (via Elsevier 1996 to 26/Sep/2013); CENTRAL (via Cochrane Library to 
issue 9 of 12, 2013); DARE (via Wiley, to issue 3 of 4, July 2013); CINAHL (via Ebsco to 
29/Sep/2013); PsycINFO (via OvidSP 1806 to September Week 4 2013); AMED (via OvidSP, 
1985 to September 2013).  Searches for ongoing clinical trials were also run in ClinicalTrials.gov 
(www.clinicaltrials.gov/ 05/12/2013), International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/ 05/12/2013), Current Controlled Trials (http://www.controlled-
trials.com/ 05/12/2013), Natural Standard (http://www.naturalstandard.com/ 05/12/2013), as well 
as various drug and device regulatory approval sites.   Further studies were identified in Web of 
Science and Scopus (18/Mar/2014) by carrying out citation searches for studies citing included 
studies, as well as by examining their reference lists. The search strategy outlined in Figure 1, 
combined the 2 following concepts: cannabinoids and rheumatic diseases, using text words and 
relevant indexing.  The full MEDLINE strategy was applied to all databases, with modifications 
to search terms as necessary. 
 
Inclusion and exclusion criteria 
Randomized controlled trials (RCTs) that assessed at least one outcome of pain, sleep 
disturbance and/or quality of life in rheumatic diseases, with comparison of a cannabinoid with 
placebo or an active control were included, without limitations for study duration and patients 
included per treatment arm. Only articles with full text in either English or French were included. 
 
Quality assessment 
Risk of bias in included studies was assessed independently by two authors (PSM and MAF) 
using the criteria outlined in the “Risk of bias” tool in the Cochrane Handbook for systematic 
Reviews of Interventions and adapted from those used by the Cochrane and Pregnancy and 
Childbirth Group [14]. We resolved any disagreement by discussion. The following were 
assessed for each study: 1.Random sequence generation (selection bias); 2. Allocation 
concealment (selection bias); 3. Blinding of outcome assessment (detection bias); 4. Incomplete 
outcome data (attrition bias due to amount, nature and handling of incomplete outcome data); 5. 
Size (possible bias confounded by small size, with low risk of bias if there were 200 participants, 
unclear risk with 50 to 200 participants, and high risk if there were fewer than 50 
participants)Risk of bias within each study was assessed as low (when there was low risk for all 
domains), unclear (if there was unclear risk for one or more domains), and high (if there was 
high risk for one or more key domains). GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) was used to rate the overall quality of the evidence, with GRADE 
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ratings of very low-, low-, moderate, or high-quality evidence reflective of the extent to which 
we are confident in the overall effect of a treatment [15]. 
 
Data extraction 
Data were recorded on a standardized form by two of the authors (MAF and PSM).  The 
following information was recorded for each study: first author, year of publication, specific 
agent studied, study design, sample size, specific disease studied, and outcome measurements 
reported. Where possible data on the following outcomes were recorded: pain intensity, sleep 
quality, and health-related quality of life. Adverse events reported for each study were recorded 
with attention to the following: somnolence, cognitive complaints, and gastrointestinal 
complaints. The number of patients dropping out due to adverse events (tolerability), as well as 






The electronic database search and initial screening for eligible studies yielded 1663 articles after 
removal of duplicates, with 22 studies selected for full text review (see Figure 2 for a PRISMA 
flow diagram).  Excluded were survey reports, observational studies, case series, case reports and 
commentaries, with 8 remaining articles [16-23].  Of these four were excluded: two included 
patients with pain due to causes other than rheumatic diseases, one was an open-label study 
examining the effect of product delta-9 tetrahydrocannabinol (∆
9
-THC) on experimentally 
induced pain, and the other was an open-label report of cannabis use in patients with 
fibromyalgia (FM) [16-19].  
 
Characteristics of included studies 
There were four controlled studies that met inclusion criteria, but as studies included patients 
with different rheumatic diseases and different products were used as treatments, the existing 
information did not allow for meta-analysis, and therefore is reported only as a qualitative 
(narrative) review. The four studies comprised 201 patients with rheumatic diseases, of which 58 
patients had rheumatoid arthritis (RA), 71 had fibromyalgia (FM) and 74 were diagnosed with 
osteoarthritis (OA). A single study examined the effect of nabiximols in RA, two studies 
examined nabilone in FM, and one study reported on the effect of a FAAH inhibitor in OA 
(Table 1). The single study of FAAH inhibitor was stopped at interim analysis for futility. For 
the remaining 3 completed trials, duration was from 5-8 weeks [20, 22, 23]. All 3 completed 
studies had at least two of the five key domains assessed as having a high risk of bias with the 
conclusion that all studies had an overall high risk of bias (Table 2). 
 
Specific cannabinoid preparations 
 
Nabiximols 
A single study examined the effect of nabiximols, phytocannabinoids extracted from cannabis and 
supplied as an oromucosal spray, compared to placebo in RA [20]. This study had a high risk of 
bias for 3 of the five key domains assessing risk for bias. In this double blind randomized trial of 
58 patients with RA, over a 5-week period, improvements in pain, sleep quality and 28-joint 
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Disease Activity Score were observed. A total of 4 patients withdrew from the study, 1 from the 
active group for an unrelated surgery, and 3 from the placebo group due to adverse events (2 
serious not further characterized, 1 not described). Adverse events were more commonly reported 
for the active treatment, with dizziness in 26%, dry mouth in 13%, light-headedness in 11% and 
nausea and falls in 6%, with less frequent reports of constipation, arthritic pain and headache. 
Constipation and malaise was identified as severe for each of the 2 patients in the active group 
reporting this adverse effect.  
 
There have been no RCTs of nabiximols in patients with other inflammatory rheumatic condition, 
OA, soft tissue rheumatism or FM.  
 
Nabilone 
There are two trials of nabilone for the treatment of symptoms of FM that included a total of 71 
patients [22, 23]. In the first study of 40 FM patients observed over an 8-week period, with a 4-
week active treatment phase, nabilone was associated with statistical improvement in pain and 
the quality of life measurement, the fibromyalgia impact questionnaire (FIQ) [22]. Nabilone was 
initiated at 0.5mg at bedtime and could be titrated up to 1mg twice a day. Seven patients 
withdrew from the study, 5 in the treatment group (2 without reason, 2 dizziness, and /or 
disorientation, nausea and headache, 1 drowsiness and fatigue) and 2 in the placebo group (1 
without a reason, 1 headache). Risk for bias was assessed as high for 2 of 5 key domains 
assessing bias. With no differences in effect observed between the groups at the 2 week 
assessment, the treatment group showed statistically improved pain and FIQ at 4 weeks. Side 
effects were more common for the active treatment group throughout the study period, with 
drowsiness reported by almost half on active treatment, dry mouth in a third, vertigo and ataxia 
in a fifth, and fewer reporting confusion, poor concentration, headache, anorexia and dysphoria 
or euphoria. There were no serious adverse events reported for the study. 
 
The second study was a randomized, double-blind, crossover study examining the effect of 
nabilone compared to amitriptyline on sleep disturbance in 31 FM patients [23]. Conducted over 
a 6-week period, with each subject receiving each drug for a two week period with a two week 
washout, non-inferiority of nabilone compared to amitriptyline was observed for some sleep 
measures. Nabilone was initiated at 0.5mg/day with option to increase to 1mg/day, and 
amitriptyline was initiated at 10mg/day with option to increase to 20mg. Three patients withdrew 
from the study, 1 for noncompliance with study protocol, 1 for lack of effect and 1 for side 
effects of edema, dizziness, nausea and insomnia after a single dose. Risk of bias was high for 2 
of the 5 key domains assessed. With both agents showing a positive effect on sleep, nabilone 
showed a marginal advantage when sleep was assessed by the Insomnia Severity Index, but not 
for the Leeds Sleep Evaluation Questionnaire [23]. There were no significant differences 
between treatments for effect on pain or quality of life. Adverse events of dizziness, drowsiness, 
nausea and dry mouth were more frequently reported in the nabilone treatment group. There 
were no serious adverse events.  
 
There have been no studies of nabilone in patients with inflammatory rheumatic conditions, OA 
or soft tissue rheumatism.  
 
Fatty acid amide hydrolase (FAAH) inhibitor 
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A single study in 74 patients with OA examined the effect of a FAAH inhibitor, PF-04457845, 
compared to naproxen as an active comparator [21]. This study was stopped at the interim 
analysis for futility. While naproxen showed reduction in pain compared to placebo, the FAAH1 
inhibitor did not demonstrate difference from placebo, although the agent was well tolerated with 
a safety profile similar to placebo.  There have been no studies of any similar agent used in 
inflammatory rheumatic conditions, soft tissue rheumatism or FM.  
 
Dronabinol 
There have been no studies of dronabinol in patients with any rheumatic disease. 
 
Herbal cannabis 






This systematic review has revealed a dearth of studies examining the effects of cannabinoids in 
a small number of patients with rheumatic diseases. Amongst a vast array of rheumatic 
conditions, cannabinoid effects have only been studied in RA, FM and OA, with the latter study 
prematurely terminated due to lack of efficacy. All studies included in this analysis were 
assessed as having a high risk of bias, with particular note that all studies comprised extremely 
low numbers of participants leading to the possibility that results may be completely random.  
While statistical improvements in pain and effect on sleep were observed, troublesome quasi 
neurological side effects of altered perception, dizziness, and drowsiness, as well as 
gastrointestinal effects were common. With only pharmaceutical preparations studied to date, 
and without any formal study of herbal cannabis preparations, no comment can be made 
regarding effects for herbal cannabis preparations in patients with rheumatic diseases. Based on 
the GRADE approach, there is low-quality evidence suggesting that cannabinoids may be 
associated with improvements in pain and sleep quality in RA and FM. 
 
Clinical positive effects for the studies assessed in this review must be balanced by the reported 
adverse events. For the study of nabiximols in RA, the selected primary outcome measure of 
improved morning pain on movement was achieved, as well as some other secondary outcome 
measures of morning pain at rest, sleep quality and a global disease activity score, but measures 
of pain intensity were unchanged [20]. The authors further stated that although the differences 
observed were small and also variable across the population, they represent “benefits of clinical 
relevance”.  These selected measurements of change in pain and sleep quality are unique and not 
the usual standard for measurements of pain response or change in sleep. Other than limited 
demographic information, no other information is provided regarding RA disease status such as 
duration of disease, or concomitant treatments for disease modification or pain management, 
which further complicates interpretation of results. Similarly, the two studies of nabilone effect 
in FM, while reaching statistical significance may have less clinical meaningful effect when 
efficacy and side effects are weighed simultaneously [22, 23]. Although reported as significant, a 
1.43cm change in pain from baseline (on the 10cm visual analogue scale), and a 10.76 (16%) 
change for the FIQ, are of questionable meaningful clinical effect [22]. The 16% reduction in 
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FIQ total score does however exceed the reported minimally important difference for a change of 
14% in the FIQ total score [24].  In the second study, nabilone had a marginally better effect on 
sleep compared to amitriptyline, but with effects on pain, mood and quality of life that were 
similar, but not superior, to those observed for amitriptyline [23]. 
  
Adverse events related to pharmaceutically prepared cannabinoid treatments were common, but 
although not serious, may be sufficiently troubling to impact wellbeing. For all three studies, 
between a quarter to a half of subjects reported side effects with quasi neurological effects of 
dizziness, drowsiness, and some form of cognitive effect reported for all. Gastrointestinal effects 
of dry mouth, nausea and constipation were also reported in each of the studies. The frequency of 
side effects noted in the placebo-controlled study of nabilone prompted the authors to suggest 
that a gradual introduction and titration of nabilone should be considered for future studies [22]. 
It is however reassuring to note that there were no active treatment-related serious adverse events 
reported for any of the studies.  
 
Two recent systematic reviews that examined the effect of cannabinoids for treatment of chronic 
non-cancer pain, reported superiority of cannabinoids to placebo for analgesic effect, with some 
studies also showing improvement in sleep [25, 26]. Notably, neuropathic pain was the most 
commonly identified pain mechanism, rather than a specific musculoskeletal complaint. It is 
however increasingly appreciated that many musculoskeletal pain conditions have a considerable 
overlap of neuropathic pain mechanisms [27].  Any therapeutic effect must however be balanced 
with adverse effects, with numbers needed to harm (NNH) calculated to be between 5 and 8 for 
events affecting motor function, altered perception and altered cognition, emphasizing the 
narrow therapeutic window associated with currently available pharmaceutically prepared 
cannabinoid treatments.   
 
There are no RTCs examining the effect of herbal cannabis in patients with rheumatic diseases. 
The lack of research using herbal cannabis may be attributed to the contentious status of 
cannabis as a highly controlled substance, with strong restrictions to access for research 
purposes, and as such access to herbal cannabis for therapeutic use has been primarily driven by 
patient-led initiatives at the legal and political levels. Physicians are therefore reliant on 
extrapolation from studies in other conditions. Information about herbal cannabis for the 
management of rheumatic complaints may be derived from small population surveys of  persons 
with chronic pain conducted in the United Kingdom, Canada and Australia [3-5].  
Musculoskeletal or arthritis complaints by self-report are identified for between 15% to almost 
40% of subjects, with variable outcome measures used. A single study reported dosing of 2 
grams of herbal cannabis use a day for about 40% subjects, but without report of concomitant 
treatments for any of the studies [3-5]. Although these studies did not disaggregate respondents 
reporting rheumatic conditions, across all three studies the vast majority of patients perceived 
herbal cannabis to be therapeutically effective. Recreational use of cannabis either before 
medicinal use or concurrent was common for all three studies. Therefore on the strength of the 
evidence for the published literature, no conclusions for efficacy or safety of herbal cannabis in 
rheumatic conditions can be made. However, the safety profile of cannabis may compare 
favorably to current available therapies to treat rheumatic pain.  
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In sum there is currently no sound evidence on which to base any recommendation for use of 
cannabinoids for symptom relief in the rheumatic conditions. As one may expect, this lack of 
evidence translates into the lack of confidence expressed by Canadian rheumatologists regarding 
their knowledge of cannabinoids in general [13].  In light of the extensive scientific but limited 
clinical evidence, patients may have numerous reasons to advocate for use of cannabinoids in 
general and herbal cannabis in particular.  These include the poor performance for current 
available pain therapies, scepticism about the pharmaceutical industry, anecdotal and media 
reports attesting to the efficacy of herbal cannabis, familiarity with the agent because of past 
recreational use, and knowledge that cannabis has been used for millennia for various reasons 
including medicinal relief.  
 
Findings on efficacy and tolerability issues can also be found in uncontrolled trials of 
cannabinoids. Problems with tolerability are however commonly reported for all current 
analgesic agents. In a study of nine FM patients, orally administered ∆
9
-THC reduced electrically 
induced pain as well as daily pain report, with five of the nine subjects withdrawing due to 
treatment related side effects [17]. In a second uncontrolled study comparing FM patients who 
used (28 patients) or did not use cannabis (28 patients) for therapeutic effect, users reported 
reduction in pain scores two hours after herbal cannabis use [19]. Whether patients were regular 
users of medicinal cannabis, or nonusers  did not influence measurements of function by the 
Short Form 36 Health Survey physical component summary score or the FIQ at baseline [19] .   
 
Limitations and strengths  
The conclusions of this systematic review for cannabinoid use in rheumatology practice are limited 
by the weakness of the evidence available. While four RCTs were identified, the studies were 
extremely small, of short duration and only included patients with RA, FM and OA. Small sample 
size introduces a high risk of bias for all 3 completed studies and represents the most important 
limiting factor for interpretation of the results. There has only been a single study that has 
examined the effect of modulation of the endocannabinoid system in a homogenous  patient group 
with knee OA, without any difference from placebo for either efficacy or side effects [21].  Our 
search strategy was comprehensive and conducted by a qualified librarian to ensure that all the 
current available studies were accessed. 
 
Conclusion and implications for practice, policy or future research 
In view of the considerable limitations of the studies examined in this review, including small 
sample sizes, short duration, only modest efficacy and a high rate of mild to moderate adverse 
effects, it is not currently possible to recommend this category of treatments as therapy for 
patients with rheumatic diseases. Any conclusions based on these studies remain tenuous and call 
for larger, well controlled clinical trials to better understand potential benefits and risks as 
pertaining to rheumatic conditions. In addition, the absence of any study of herbal cannabis in 
rheumatic diseases precludes any recommendation for use, with particular policy implications as 
governments worldwide, responding to patient demand for access, are expanding the authorized 
medical use of herbal cannabis, with rheumatic diseases commonly cited as a reason for use. 
Further research is clearly needed to improve our understanding of the therapeutic potential and 
limitations of cannabinoids for the treatment of rheumatic disorders. 
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Figure 1: Medline search strategy for systematic review of cannabinoid effects in rheumatic 
diseases 
 
1 exp Cannabaceae/  
2 Endocannabinoids/  
3 exp Receptors, Cannabinoid/  
4 exp Cannabinoid Receptor Modulators/  
5 exp Cannabinoids/  
6 Marijuana Smoking/  
7 (cannab$ or mari?uana$ or cannador or bhang$ or ganja$ or has?hi?h$ or hemp 
or c indica or charas).mp.  
8 endocannabinoid$.mp.  
9 (sativex or nabiximol$ or gw1000 or gw-1000 or sab-378 or sab378).mp.  
10 phytocannab$.mp.  
11 ((CB1 or CB2) adj2 receptor$).mp.  
12 (nabilone or nabidiolex or dimethylcannab$ or methylcannab$ or cesamet$ or 
"109514").mp.  
13 (hydroxydronabinol or dronabinol or tetrahydrocannabinol or tetrahydrocannabinol 
or carboxytetrahydrocannabinol or thc or ea1477 or ea-1477 or marinol or 
qcd84924 or qcd-84924 or tetranabinex or jwh133 or jwh-133 or sp-104).mp.  
14 (arachidon?ylglycerol or (arachidon$ adj2 glycerol)).mp.  
15 (alujemic acid$ or ct3 or ct-3 or ip751 or ip-751).mp.  
16 (anandamide or virodamine or arachidon?ylethanolamide or methanandamide 
or am356 or am-356).mp.  
17 (oleoylethanolami?e or (ethanolami?e adj2 oleoyl)).mp.  
18 (de?acetyllevonantradol or nantradol$ or levonantradol$ or cp50556 or 
cp505561 or cp-50556 or cp-505561 or cp44001 or cp440011 or cp-44001 or cp- 
440011).mp.  
19 ((cp44 or cp-44) adj2 "001").mp.  
20 ((cp50 or cp-50) adj2 "556").mp.  
21 (dexanabinol$ or hu-211 or hu-210 or hu211 or hu210).mp.  
22 (noladin or hu310 or hu-310).mp.  
23 (palmidrol or impulsin or palmitoylethanolamide).mp.  
24 fatty acid amid$.mp.  
25 FAAH.mp.  
26 or/1-25  
27 Rheumatology/  
28 Collagen Diseases/  
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9 Connective Tissue Diseases/  
0 Joint Diseases/  
1 Musculoskeletal Diseases/  
2 Bone diseases/  
3 Musculoskeletal System/  
4 Muscular Diseases/  
5 Rheumatic Diseases/  
6 exp Arthritis, Rheumatoid/  
7 Fibromyalgia/  
8 exp Osteoarthritis/  
9 Hyperostosis/  
0 Ossification of Posterior Longitudinal Ligament/  
1 Calcinosis/  
2 Ossification, Heterotopic/  
3 Polymyalgia Rheumatica/  
4 exp Spondylosis/  
5 exp Spinal Osteophytosis/  
6 exp Spondylitis/  
7 exp Back Pain/  
8 Neck Pain/  
9 Neck/  
0 exp Joints/  
1 Pain/  
2 49 and 51  
3 50 and 51  
4 exp Musculoskeletal Pain/  
5 exp Arthralgia/  
6 Arthritis/  
7 exp Lupus Erythematosus, Systemic/  
8 Scleroderma, Localized/  
9 exp Scleroderma, Systemic/  
0 exp Myositis/  
1 Sacroiliitis/  
2 Joint Instability/  
3 Ligaments, Articular/  
4 30 and 63  
5 rheuma?t$.tw.  
6 (collagen$ adj2 (disease$1 or condition$ or disorder$1 or syndrome$1)).tw. 
7 collagenos?s.tw.  
8 (connective tissue$ adj2 (disease$1 or condition$ or disorder$1 or syndrome$1 
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or defect or dysplasia)).tw.  
9 ((joint$1 or articula$) adj2 (disease$1 or condition$ or disorder$1 or 
syndrome$1 or pain$ or ache$ or defect or deformit$ or instabilit$ or hypermobilit$ or 
hyper-mobilit$ or laxit$ or lax or hyperextensibilit$ or hyper-extensibilit$)).tw.  
0 ((bone$ or muscul$) adj2 (disease$1 or condition$ or disorder$1 or 
syndrome$1 or pain$ or ache$ or hypertroph$)).tw.  
1 still$ disease$1.tw.  
2 ((caplan or felty$ or sjo?gren$ or sicca) adj2 syndrome$1).tw.  
3 (fibrom?algi$ or fibrositi$).tw.  
4 (myofascial adj2 pain$).tw.  
5 (arthriti$ or osteoarthr$ or polyarthr$ or arthralgia or arthropath$).tw.  
6 (Longitudinal Ligament$ adj2 (ossif$ or calcif$)).tw.  
7 (Forestier or Certonciny or polymyalgia or poly-myalgia or peri-extra-articular or 
pseudopolyarthriti$).tw.  
8 spondylo$.tw.  
9 ((spine or spinal or lumbar) adj2 (osteophytos?s or osteo-phytos?s or 
tuberculos?s)).tw.  
0 hyperostos?s.tw.  
1 (spondyliti$ or dis?iti$ or spondyl?arthriti$ or spondyl?arthropath$).tw.  
2 (reiter$ adj2 (syndrome$1 or disease$1)).tw.  
3 (pott$1 adj2 (disease$1 or paraplegia)).tw.  
4 ((back or vertebr$) adj2 pain$).tw.  
5 (backache$1 or back ache$1).tw.  
6 lumbago$.tw.  
7 ((neck or cervical) adj2 (pain$ or ache$)).tw.  
8 (cervicalgia$1 or cervicod?nia$1 or neckache$1).tw.  
9 ((wrist$1 or hand$1 or elbow$1 or shoulder$1 or spin$2 or knee$1 or hip$1 or 
ankle$1 or f??t) adj2 (pain$ or ache$)).tw.  
0 (lupus or libman-sack$1).tw.  
1 (scleroderma$1 or dermatosclerosis or dermato-sclerosis or morphea$1).tw. 
2 (systemic adj2 scleros?s).tw.  
3 ((CREST or CRST) adj2 syndrome$1).tw.  
4 calcinos$.tw.  
5 (inflammat$ adj2 (myopath$ or muscle disease$1)).tw.  
6 Fibrodysplasia Ossificans.tw.  
7 (inclusion body adj2 myopath$).tw.  
8 (myositi$ or dermatomyositi$ or dermatopolymyositi$ or polymyositi$ or 
pyomyositi$).tw.  
9 (sacroiliiti$ or sacro-iliiti$).tw.  
00 ((hypermobility or hyper-mobility) adj2 (syndrome$1 or disease$1)).tw.  
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01 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 
or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 52 or 53 or 54 or 55 or 56 or 57 or 
58 or 59 or 60 or 61 or 62 or 64 or 65 or 66 or 68 or 69 or 70 or 71 or 72 or 73 or 74 
or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 
89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100  
02 26 and 101  
03 exp clinical trial/ or randomi?ed.tw. or placebo$.tw. or dt.fs. or randomly.tw. or 
trial$1.tw. or group$1.tw.  
04 102 and 103  
05 limit 104 to animals  
06 limit 105 to humans  
07 105 not 106  
08 104 not 107  
09  remove duplicates from 108  
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PRISMA Flow Diagram 
 
Records identified through 
database searching 
(n =2230) 
Additional records identified 
through other sources  
(n =660) 





(n =1641   ) 
Full-text articles assessed 
for eligibility 
(n =22   ) 




Review article n=7 
Not RCT n=2 
Survey report n=4 
Other pain conditions n=4 
Observational study n=1 
 
Studies included in 
qualitative synthesis  
(n = 4 ) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =  0 ) 
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Table 1. RCTs assessing cannabinoids in the treatment of rheumatic conditions 
 
*irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845 
AE adverse events, DAS28 28-joint disease activity score, FIQ Fibromyalgia Impact Questionnaire, ISI Insomnia Severity Index, LSEQ Leeds Sleep evaluation Questionnaire, SF-





Population Outcome measure Duration 
treatment 
Efficacy Safety Comments and 
risk of bias 








- Morning pain on movement (VAS) 
Secondary:  
- Morning pain at rest (VAS) 
- Sleep quality (VAS) 
- Morning stiffness (VAS) 
- SF-MPQ 
- DAS28 
5 weeks Improved pain on 
movement, pain at rest, sleep 
quality, DAS28 and  SF-
MPQ 
2 serious AEs in placebo 
group 
 
No withdrawals due to AEs 
in treatment  group 
 
Dizziness, dry mouth, light 
headed, nausea, falls 
 
JADAD 3High risk of 
bias 
No comment regarding 
RA disease modifying 
treatment 








- Pain (10-cm VAS) 
Secondary: 
- Tender points 
- Tender point threshold 
- FIQ depression 
- FIQ fatigue 
- FIQ anxiety  
- FIQ total score 
 
8 weeks Improved pain, FIQ anxiety 
and FIQ total score  
No serious AEs 
 
3 withdrawals due to AEs in 
treatment group 
 
Drowsiness, dry mouth, 
vertigo, cognitive effects 
JADAD 3High risk of 
bias 
No difference from 
placebo at  2weeks  
 









- Quality of sleep (ISI and LSEQ) 
Secondary: 
- MPQ  
- Profile of Mood State 
- FIQ 
- Global satisfaction with treatment 
 
2 weeks each 
study period and 
2 weeks 
washout 
Improved ISI  
No differences for LSEQ, 
MPQ, mood, FIQ 
No serious AEs 
 




nausea, dry mouth 
JADAD 5High risk of 
bias 
Nabilone  judged non 
inferior to amitriptyline. 
 
Huggins et al. 
(2012) 
PF-04457845* 
(placebo or  
naproxen  500mg 
bid vs. placebo) 
Osteoarthritis knee 
(n=74) 
- WOMAC pain  
- WOMAC stiffness 
- WOMAC physical function 
- WOMAC total score 
- Daily pain 
- Use of rescue medication 
2 weeks Study stopped at interim 
analysis due to futility 
No serious AEs JADAD 4Risk of bias 
not applicable as  
Sstudy stopped at 
interim due to futility 
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Table 2. Risk of bias assessment for randomized controlled trials of cannabinoids for rheumatic diseases 
 Blake Ware Skrabek Huggins 
Random sequence Low Low Unclear Low 
Allocation concealment Unclear Low Low Low 
Blinding outcome High Unclear Unclear Low 
Incomplete outcome data High High High Not applicable 
Size High High High High 
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